Droia Oncology Ventures is a specialist investor, dedicated to the fight against cancer. Droia invests in promising new cancer therapies, and accelerates their progress by actively supporting young drug development companies to achieve clinical proof of concept with their lead programs. Droia has an in-house team of drug development professionals who accompany the programs closely and provide hands-on support.
Droia invests in early financing rounds and also incubates new companies. Since cancer is a global disease and cancer research a global endeavour, Droia invests globally.
For life science companies, ultimate success should be measured in effective patient benefit. Droia invests in young companies that employ novel science to develop the most promising and impactful oncology therapies.
Promising therapies will have a material impact on patient prognosis, measured as a function of the severity of the unmet medical need addressed, the improvement in therapeutic benefits as compared to standard of care, and the feasibility of development.
Novel science can innovate in terms of mechanism of action, target, modality, specificity, toxicity,… Above all, novel therapies should be sufficiently differentiated to earn their place among competing therapies in the future standard of care.
Droia actively participates in the development of the portfolio companies. We aim to support portfolio companies at least up to clinical proof of concept. To this end, Droia’s development team has experience in translational development, clinical oncology and entrepreneurship. Droia’s team can assist where useful on preclinical, clinical & CMC development, on IP & regulatory affairs, on licensing, finance & transactions and on general company building. Droia’s network of oncology leaders gives us access to top-level institutions and KOL’s around the world and allows our portfolio companies to benefit from a global knowledge base.
ARCUS Biosciences (Hayward, California) develops small-molecules and antibodies to compose proprietary immune-oncology combinations. The company targets tumor related immune suppression, enhanced APC function and immune cell efficacy.
Aura Biosciences (Cambridge, Massachusetts) develops tumor targeted viral-like nanoparticles which can encapsulate a wide range of payloads. Aura’s lead product is in clinical trials against ocular melanoma.
Bioncotech (Madrid, Spain) develops nanocomplexes of synthetic dsRNA that target PAMP receptors and TLRs to induce powerful immune responses. Bioncotech is clinically evaluating several immune-oncology combinations with its lead product.
Convert Pharmaceuticals (Liège, Belgium) develops tumor microenvironment modulated prodrugs, small molecules that are inert upon administration but become potent anti-cancer agents upon reaching the tumor.
Cristal Therapeutics (Maastricht, The Netherlands) develops a polymeric nanoparticle drug delivery platform enhancing the PK properties of chemotherapeutic or nucleotide payloads and improving their uptake in the tumor microenvironment.
NormOxys (Boston, Massachusetts) develops a small molecule that affects tumor metabolism, reverses hypoxia and normalizes vasculature around cancer cells, sensitizing tumors to immune therapy, chemotherapy or radiotherapy.
Octimet (Beerse, Belgium) is developing a new generation of highly selective MET kinase inhibitors with augmented therapeutic index. The lead compound was licensed from J&J and is being clinically tested in specific MET mutated patient populations.
PACT Pharma (Hayward, California) develops neoantigen-specific adoptive TCR T-cell therapies. PACT’s proprietary neoantigen identification technology advances the feasibility, potency and affordability of personalized cell therapy for cancer.
* Representing Axis Advice sprl
* representing MARA Consulting BVBA
* representing Primix Bioventures bvba
* representing Onko bvba
* representing XIA bvba
DROIA is currently recruiting for its investment and development team. The team scouts for new opportunities, evaluates companies and projects, manages the investment or exit process and works with the portfolio companies on their progress.
Team members work closely with the portfolio companies at management or board level, and play a hands-on role in all aspects of the drug development process.
DROIA is an entrepreneurial environment, where everyone is above all committed to making a difference in the fight against cancer.
Applicants should have relevant experience in biomedical science, drug development and / or life science investing.
35, Allée Scheffer
Tel. +352 203 01 236
Tel. +32 2 880 67 30